EyePoint Pharmaceuticals, Inc.
EYPTEyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
Drugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Aug 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How EYPT's past catalysts played out
FAI insert
Non-Infectious Uveitis
FAI Insert administered using the Mk II inserter
Non-Infectious Uveitis
EYP-1901
Diabetic Macular Edema
Latanoprost ophthalmic solution
Ocular Hypertension
AKB-9778
Nonproliferative Diabetic Retinopathy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FAI insert | Phase 3 | Non-Infectious Uveitis | - | - |
FAI Insert administered using the Mk II inserter | Phase 3 | Non-Infectious Uveitis | - | - |
EYP-1901 | Phase 3 | Diabetic Macular Edema | - | - |
Latanoprost ophthalmic solution | Phase 2 | Ocular Hypertension | - | - |
AKB-9778 | Phase 2 | Nonproliferative Diabetic Retinopathy | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in EyePoint Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in EyePoint Pharmaceuticals, Inc.'s (EYPT) pipeline across Phase 3, Phase 2. Its lead program is FAI insert (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is EyePoint Pharmaceuticals, Inc.'s next FDA catalyst?→
EyePoint Pharmaceuticals, Inc.'s (EYPT) next tracked catalyst is a Phase 3 expected August 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EYPT biotech catalysts?→
Add EYPT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow EyePoint Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.